CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis ("ATTRv")

Stock Information for Centogene N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Centogene N.V.

CENTOGENE Receives Nasdaq Non-Compliance Notice
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCR? Deficiency
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
CENTOGENE Explores Strategic Alternatives
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
CENTOGENE Receives French Research Tax Credit Accreditation
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using Multiomics

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.